Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Edward, Pequignot"'
Autor:
Stephan A. Grupp, David L. Porter, Carl H. June, Bruce L. Levine, Gerald Wertheim, Farzana Nazimuddin, Jason C. White, Stefan Rose-John, Zhaohui Zheng, Susan R. Rheingold, Colleen Callahan, Richard Aplenc, Robert A. Berg, Julie C. Fitzgerald, Scott L. Weiss, David M. Barrett, Jeffrey Finklestein, Fang Chen, Vanessa E. Gonzalez, Edward Pequignot, Noelle Frey, Shannon L. Maude, J. Joseph Melenhorst, Pamela A. Shaw, Simon F. Lacey, David T. Teachey
Supplementary methods, statistical methods, results, tables, and figures. Supplementary Table 1. CRS grading system. Supplementary Table 2. Samples collected and time points on the trials. Supplementary Table 3. HLH diagnostic criteria. Supplementary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b25964fa4b6a8e0a19d4230c9511d15
https://doi.org/10.1158/2159-8290.22532237
https://doi.org/10.1158/2159-8290.22532237
Autor:
Simon F. Lacey, Caroline Diorio, Edward M. Behrens, David M. Barrett, David L. Porter, Fang Chen, Jenny Bush, Bruce L. Levine, Alena Orlenko, Edward Pequignot, J. Joseph Melenhorst, Jason H. Moore, Natalka Koterba, Pamela A. Shaw, Richard Aplenc, Donglan Zhang, Michele Paessler, David T. Teachey, Vanessa E. Gonzalez, Don L. Siegel, Hamid Bassiri, Stephan A. Grupp, Megan M. Davis, Nuala J. Meyer, Scott L. Weiss, Amanda M. DiNofia, Shannon L. Maude, Carl H. June
Publikováno v:
Blood Adv
Chimeric antigen receptor (CAR) T-cells directed against CD19 have drastically altered outcomes for children with relapsed and refractory acute lymphoblastic leukemia (r/r ALL). Pediatric patients with r/r ALL treated with CAR-T are at increased risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9305269a592995d1690ebfa89bd814dc
https://doi.org/10.1182/bloodadvances.2020002592
https://doi.org/10.1182/bloodadvances.2020002592
Autor:
Xinhe Shan, Elizabeth O. Hexner, Noelle V. Frey, Daniel J. Landsburg, Simon F. Lacey, Carl H. June, Saar Gill, Sunita D. Nasta, Jakub Svoboda, Edward A. Stadtmauer, Anthony R. Mato, Alison W. Loren, Elizabeth Veloso, Avery L. Gaymon, Wei-Ting Hwang, Bruce L. Levine, Stephen J. Schuster, J. Joseph Melenhorst, David L. Porter, Edward Pequignot
Publikováno v:
J Clin Oncol
PURPOSE To describe long-term outcomes of anti-CD19 chimeric antigen receptor T (CART) cells in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). METHODS Between January 2013 and June 2016, 42 patients with relapsed or refracto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0df1520497d05910a582579c8080dd59
https://doi.org/10.1200/jco.19.03237
https://doi.org/10.1200/jco.19.03237
Autor:
Nirav N. Shah, Elizabeth O. Hexner, Selina M. Luger, Pamela A. Shaw, David L. Porter, Carl H. June, Simon F. Lacey, Alison W. Loren, J. Joseph Melenhorst, Joan Gilmore, Bruce L. Levine, Saar Gill, Stephan A. Grupp, Noelle V. Frey, Alexander E. Perl, Edward Pequignot, James K. Mangan, Shannon L. Maude
Publikováno v:
J Clin Oncol
PURPOSE The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7288241b46918d4a3bfb340684a45f38
https://doi.org/10.1200/jco.19.01892
https://doi.org/10.1200/jco.19.01892
Autor:
Saar Gill, Vanessa Vides, Noelle V. Frey, Elizabeth O. Hexner, Susan Metzger, Megan O'Brien, Wei-Ting Hwang, Jennifer L. Brogdon, Megan M. Davis, Joseph A. Fraietta, Avery L. Gaymon, Whitney L. Gladney, Simon F. Lacey, Anne Lamontagne, Anthony R. Mato, Marcela V. Maus, J. Joseph Melenhorst, Edward Pequignot, Marco Ruella, Maksim Shestov, John C. Byrd, Stephen J. Schuster, Donald L. Siegel, Bruce L. Levine, Carl H. June, David L. Porter
Publikováno v:
Blood advances. 6(21)
In chronic lymphocytic leukemia (CLL) patients who achieve a complete remission (CR) to anti-CD19 chimeric antigen receptor T cells (CART-19), remissions are remarkably durable. Preclinical data suggesting synergy between CART-19 and the Bruton’s t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8def37648cb5d5a699edfc25ad44fdeb
https://pubmed.ncbi.nlm.nih.gov/35349631
https://pubmed.ncbi.nlm.nih.gov/35349631
Autor:
Megan Davis, Lester Lledo, Noelle V. Frey, Don L. Siegel, Bruce L. Levine, Saar Gill, Wei-Ting Hwang, Elizabeth O. Hexner, Natalie F. Uy, David L. Porter, Alison W. Loren, Stephan A. Grupp, J. Joseph Melenhorst, Simon F. Lacey, Joan Gilmore, Stephen J. Schuster, Edward Pequignot, Joseph A. Fraietta, Carl H. June
Publikováno v:
Blood. 136:30-32
INTRODUCTION Anti-CD19 CAR T-cell immunotherapy is promising for patients with relapsed/refractory CLL. Hypogammaglobinemia can result from normal CD19+ B-cell depletion by CAR-T cells. CLL patients are already at risk for infections due to impaired
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::300baf3a900de44bcabb0fea869c1deb
https://doi.org/10.1182/blood-2020-141224
https://doi.org/10.1182/blood-2020-141224
Autor:
Pamela A Shaw, Don L. Siegel, Andrew D. Fesnak, Christina Fasano, Kelly D. Getz, Richard Aplenc, Jennifer Brogdon, Amanda M. DiNofia, Allison Barz Leahy, Yimei Li, Megan M. Davis, Diane Baniewicz, Hongyan Liu, Lisa Wray, Carl H. June, David T. Teachey, Elizabeth O. Hexner, Stephan A. Grupp, Edward Pequignot, Bruce L. Levine, Colleen Callahan, Simon F. Lacey, Shannon L. Maude, Gerald Wertheim, Anne Chew, Chelsie Bartoszek, Regina M. Myers, Susan R. Rheingold, David M. Barrett
Publikováno v:
J Clin Oncol
PURPOSE CD19-targeted chimeric antigen receptor (CAR)–modified T cells demonstrate unprecedented responses in B-cell acute lymphoblastic leukemia (B-ALL); however, relapse remains a substantial challenge. Short CAR T-cell persistence contributes to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103c6ddb241c52b015b2819f4f73f18a
https://pubmed.ncbi.nlm.nih.gov/34156874
https://pubmed.ncbi.nlm.nih.gov/34156874
Autor:
E. Fox, Don L. Siegel, Mercy Gohil, A. Dai, D. Holland, Mark M. Davis, Edward Pequignot, Kathleen M. Haines, Jun Xu, B.L. Levine, I. Sassoon, Gabriela Plesa, Aarti Jain, F. Alvarado, Julie K. Jadlowsky
Publikováno v:
Cytotherapy. 23:S178
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a1aa77020c73f324416eabbf208635a
https://doi.org/10.1016/s1465324921005831
https://doi.org/10.1016/s1465324921005831
Autor:
Iulian Pruteanu-Malinici, Alina C. Boesteanu, Noelle V. Frey, Felipe Bedoya, Jennifer Brogdon, Don L. Siegel, Changfeng Zhang, F. Brad Johnson, Megan M. Davis, Edward Pequignot, Regina M. Young, Simon F. Lacey, Yan Wang, David L. Porter, Roddy S. O’Connor, Carl H. June, Sadik H. Kassim, Wei-Ting Hwang, David E Ambrose, Lifeng Tian, Joseph A. Fraietta, Corin L. Dorfmeier, Stefan Lundh, Bruce L. Levine, Jun Xu, Hans Bitter, Fang Chen, Irina Kulikovskaya, Nicholas Wilcox, Mercy Gohil, Harit Parakandi, Alexander C. Huang, E. John Wherry, Li Liu, J. Joseph Melenhorst, Elena Orlando, Minnal Gupta
Publikováno v:
Nature Medicine. 27:561-561
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fdbbc013a9884b7f454f421a988e602
https://doi.org/10.1038/s41591-021-01248-2
https://doi.org/10.1038/s41591-021-01248-2
Autor:
Fang Chen, Simon F. Lacey, Noelle V. Frey, Edward Pequignot, Carl H. June, David L. Porter, David T. Teachey, Stephan A. Grupp, Shannon L. Maude, J. Joseph Melenhorst
Publikováno v:
Journal of Immunological Methods. 434:1-8
T cells expressing a CD19-specific chimeric antigen receptor (CAR19) are demonstrating remarkable efficacy in hematologic malignancies. Treatment is often associated with life-threatening cytokine release syndrome (CRS) which can be effectively treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47183cfb7d7e225b5fada426636f069d
https://doi.org/10.1016/j.jim.2016.03.005
https://doi.org/10.1016/j.jim.2016.03.005